Considerations in sirolimus use in the early and late post-transplant periods

Area of Science:

• Immunology
• Pharmacology
• Nephrology

Background:

• Sirolimus is an antiproliferative immunosuppressant targeting the mammalian target of rapamycin (mTOR).
• It is a key agent in preventing acute renal allograft rejection.
• Sirolimus can be administered alongside calcineurin inhibitors, antimetabolites, or corticosteroids.

Purpose of the Study:

• To review the efficacy and safety of sirolimus in renal transplantation.
• To provide insights into optimal dosing and management strategies.
• To discuss current considerations regarding sirolimus's role in long-term outcomes.

Main Methods:

• Review of early studies and clinical data on sirolimus in renal transplantation.
• Analysis of pharmacokinetic and pharmacodynamic interactions with other immunosuppressive agents.
• Evaluation of adverse effect profiles and management strategies.

Main Results:

• Sirolimus demonstrates high efficacy in preventing acute renal allograft rejection.
• Optimal dosing strategies for sirolimus and concomitant agents have been identified.
• Understanding drug interactions is crucial for managing sirolimus-related complications.

Conclusions:

• Sirolimus is a valuable immunosuppressant in renal transplantation.
• Effective management requires familiarity with its adverse effects and drug interactions.
• Ongoing research is exploring its impact on long-term renal function, malignancies, and atherosclerosis.